Potential therapeutic effects of mTOR inhibition in atherosclerosis

British Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 1267-1279

  Kurdi, Ammar ^a   De Meyer, Guido R Y ^a   Martinet, Wim ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

atherosclerosis; metformin; mTOR; rapalogs; rapamycin

Indexed keywords

EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; PACLITAXEL; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RIDAFOROLIMUS; TACROLIMUS; TEMSIROLIMUS; UMIROLIMUS; ZOTAROLIMUS;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; DRUG ELUTING STENT; DRUG MECHANISM; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84999488401     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12820     Document Type: Review

References (155)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation 2014; 129: e28–292.
2. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410–22.
3. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011; 145: 341–55.
4. Vanepps JS, Vorp DA. Mechano-pathobiology of atherogenesis: a review. J Surg Res 2007; 142: 202–17.
5. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317–25.
6. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–95.
7. Hopkins PN. Molecular biology of atherosclerosis. Physiol Rev. 2013; 93: 1317–542.
8. Thorp E, Tabas I. Mechanisms and consequences of efferocytosis in advanced atherosclerosis. J Leukoc Biol 2009; 86: 1089–95.
9. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol 2011; 31: 1506–16.
10. Moreno PR, Purushothaman K-RR, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. Circulation 2006; 113: 2245–52.
11. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, Badimon JJ, O'Connor WN. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004; 110: 2032–8.
12. Finn AV, Jain RK. Coronary plaque neovascularization and hemorrhage: a potential target for plaque stabilization? JACC Cardiovasc Imaging. J Am Coll Cardiol 2010; 3: 41–4.
13. Kang S, Wu Y, Li X. Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. Atherosclerosis 2004; 177: 433–42.
14. Hwang I-C, Jeon J-Y, Kim Y, Kim HM, Yoon YE, Lee S-P, Kim H-K, Sohn D-W, Sung J, Kim Y-J. Statin therapy is associated with lower all-cause mortality in patients with non-obstructive coronary artery disease. Atherosclerosis 2015; 239: 335–42.
15. Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, Nordio F, Hyde CL, Cannon CP, Sacks FM, Poulter NR, Sever PS, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet Elsevier; 2015; 385: 2264–71.
16. Ruscica M, Macchi C, Morlotti B, Sirtori CR, Magni P. Statin therapy and related risk of new-onset type 2 diabetes mellitus. Eur J Intern Med 2014; 25: 401–6.
17. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, Shahawy ME, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJP. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489–99.
18. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500–9.
19. Nakatani D, Kotani J, Tachibana K, Ichibori Y, Mizote I, Asano Y, Sakata Y, Sakata Y, Sumitsuji S, Saito S, Sakaguchi T, Fukushima N, Nanto S, Sawa Y, Komuro I. Plaque regression associated with everolimus administration after heart transplantation. J Cardiol Cases 2013; 7: e155–7.
20. Lee IS, Bourantas CV, Muramatsu T, Gogas BD, Heo JH, Diletti R, Farooq V, Zhang Y, Onuma Y, Serruys PW, Garcia-Garcia HM. Assessment of plaque evolution in coronary bifurcations located beyond everolimus eluting scaffolds: serial intravascular ultrasound virtual histology study. Cardiovasc Ultrasound 2013; 11: 25.
21. Martinet W, De Loof H, De Meyer GRY. mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. Atherosclerosis 2014; 233: 601–7.
22. Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 2009; 37: 217–22.
23. Santulli G, Totary-Jain H. Tailoring mTOR-based therapy: molecular evidence and clinical challenges. Pharmacogenomics 2013; 14: 1517–26.
24. Morita M, Gravel S-P, Chénard V, Sikström K, Zheng L, Alain T, Gandin V, Avizonis D, Arguello M, Zakaria C, McLaughlan S, Nouet Y, Pause A, Pollak M, Gottlieb E, Larsson O, St-Pierre J, Topisirovic I, Sonenberg N. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab 2013; 18: 698–711.
25. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 2007; 450: 736–40.
26. Dowling RJO, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta 2010; 1804: 433–9.
27. Lamming DW, Ye L, Sabatini DM, Baur JA. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest 2013; 123: 980–9.
28. Ehninger D, Neff F, Xie K. Longevity, aging and rapamycin. Cell Mol Life Sci 2014; 71: 4325–46.
29. Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA. Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog 2012; 17: 69–95.
30. Oh WJ, Jacinto E. mTOR complex 2 signaling and functions. Cell Cycle 2011; 10: 2305–16.
31. Lamming DW. mTORC2 takes the longevity stAGE. Oncotarget 2014; 5: 7214–5.
32. Liu L, Parent CA. TOR kinase complexes and cell migration. J Cell Biol 2011; 194: 815–24.
33. Julien L-A, Carriere A, Moreau J, Roux PP. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol 2010; 30: 908–21.
34. Urbanska M, Gozdz A, Swiech LJ, Jaworski J. Mammalian target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) control the dendritic arbor morphology of hippocampal neurons. J Biol Chem 2012; 287: 30240–56.
35. Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. J Chem Biol 2008; 1: 27–36.
36. Tsang CK, Qi H, Liu LF, Zheng XFS. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007; 12: 112–24.
37. De Meyer GRY, Grootaert MOJ, Michiels CF, Kurdi A, Schrijvers DM, Martinet W. Autophagy in Vascular Disease. Circ Res 2015; 116: 468–79.
38. Schreiber KH, Ortiz D, Academia EC, Anies AC, Liao C-Y, Kennedy BK. Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins. Aging Cell 2015; 14: 265–73.
39. Lamming DW, Sabatini DM. A central role for mTOR in lipid homeostasis. Cell Metab 2013; 18: 465–9.
40. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9: 324–37.
41. van Rossum HH, Romijn FPHTM, Smit NPM, de Fijter JW, van Pelt J. Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12. Biochem Pharmacol 2009; 77: 1206–12.
42. Bauer A, Brönstrup M. Industrial natural product chemistry for drug discovery and development. Nat Prod Rep 2014; 31: 35–60.
43. Edwards SR, Wandless TJ. The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem 2007; 282: 13395–401.
44. Leung LY, Lim H-K, Abell MW, Zimmerman JJ. Pharmacokinetics and metabolic disposition of sirolimus in healthy male volunteers after a single oral dose. Ther Drug Monit 2006; 28: 51–61.
45. Cohen EEW, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res 2012; 18: 4785–93.
46. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011; 121: 1231–41.
47. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011; 10: 868–80.
48. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns R-J, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Ormiston JA. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 2014; 9: 1271–84.
49. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hébert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009; 373: 897–910.
50. Vicier C, Dieci MV, Arnedos M, Delaloge S, Viens P, Andre F. Clinical development of mTOR inhibitors in breast cancer. Breast Cancer Res 2014; 16: 203.
51. Battelli C, Cho DC. mTOR inhibitors in renal cell carcinoma. Therapy 2011; 8: 359–67.
52. Don ASA, Zheng XFS. Recent clinical trials of mTOR-targeted cancer therapies. Rev Recent Clin Trials 2011; 6: 24–35.
53. Roulin D, Cerantola Y, Dormond-Meuwly A, Demartines N, Dormond O. Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol Cancer 2010; 9: 57.
54. Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, Zhang W-G, Mahoney R, Gaydos C, Tardio L, Kim SK, Conant R, Curran K, Kaplan J, Verheijen J, Ayral-Kaloustian S, Mansour TS, Abraham RT, Zask A, Gibbons JJ. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 2010; 70: 621–31.
55. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010; 40: 310–22.
56. Serruys PW, Regar E, Carter AJ. Rapamycin eluting stent: the onset of a new era in interventional cardiology. Heart. 2002; 87: 305–7.
57. Sipahi I. CREDIT Coronary atherosclerosis can regress with very intensive statin therapy. Cleve Clin J Med 2006; 73: 937–44.
58. Thuesen L, Kelbaek H, Kløvgaard L, Helqvist S, Jørgensen E, Aljabbari S, Krusell LR, Jensen GVH, Bøtker HE, Saunamäki K, Lassen JF, van Weert A. Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT). Am Heart J 2006; 152: 1140–5.
59. Sheiban I, Villata G, Bollati M, Sillano D, Lotrionte M, Biondi-Zoccai G. Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V). Vasc Health Risk Manag 2008; 4: 31–8.
60. Stone Gw, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663–74.
61. Stone Gw, Kedhi E, Kereiakes DJ, Parise H, Fahy M, Serruys PW, Smits PC. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 2011; 124: 893–900.
62. Wessely R, Kastrati A, Mehilli J, Dibra A, Pache J, Schömig A. Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design. Eur Heart J 2007; 28: 2720–5.
63. Cho Y, Yang H-M, Park K-W, Chung W-Y, Choi D-J, Seo W-W, Jeong K-T, Chae S-C, Lee M-Y, Hur S-H, Chae J-K, Seong I-W, Yoon J-H, Oh S-K, Kim D-I, Park K-S, Rha S-W, Jang Y-S, Bae J-H, Hong T-J, Cho M-C, Kim Y-J, Jeong M-H, Kim M-J, Park SK, Chae I-H, Kim H-S. Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction: with analyses for diabetic and nondiabetic subpopulation. JACC Cardiovasc Interv 2010; 3: 498–506.
64. Sharma S, Lagisetti C, Poliks B, Coates RM, Kingston DGI, Bane S. Dissecting paclitaxel–microtubule association: quantitative assessment of the 2′-OH group. Biochemistry 2013; 52: 2328–36.
65. Verheye S, Martinet W, Kockx MM, Knaapen MWM, Salu K, Timmermans J-P, Ellis JT, Kilpatrick DL, De Meyer GRY. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol 2007; 49: 706–15.
66. Wang X, Li L, Li M, Dang X, Wan L, Wang N, Bi X, Gu C, Qiu S, Niu X, Zhu X, Wang L. Knockdown of mTOR by lentivirus-mediated RNA interference suppresses atherosclerosis and stabilizes plaques via a decrease of macrophages by autophagy in apolipoprotein E-deficient mice. Int J Mol Med 2013; 32: 1215–21.
67. Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol 2005; 46: 481–6.
68. Castro C, Campistol JM, Sancho D, Sánchez-Madrid F, Casals E, Andrés V. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27Kip1-independent pathway. Atherosclerosis 2004; 172: 31–8.
69. Gadioli ALN, Nogueira BV, Arruda RMP, Pereira RB, Meyrelles SS, Arruda JA, Vasquez EC. Oral rapamycin attenuates atherosclerosis without affecting the arterial responsiveness of resistance vessels in apolipoprotein E-deficient mice. Braz J Med Biol Res 2009; 42: 1191–5.
70. Zhao L, Ding T, Cyrus T, Cheng Y, Tian H, Ma M, Falotico R, Praticò D. Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor. Br J Pharmacol 2009; 156: 774–85.
71. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/-mice despite severe hypercholesterolemia. Atherosclerosis 2008; 198: 39–48.
72. Elloso MM, Azrolan N, Sehgal SN, Hsu P-L, Phiel KL, Kopec CA, Basso MD, Adelman SJ. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 2003; 3: 562–9.
73. Baetta R, Granata A, Canavesi M, Ferri N, Arnaboldi L, Bellosta S, Pfister P, Corsini A. Everolimus inhibits monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits. J Pharmacol Exp Ther 2009; 328: 419–25.
74. Chen WQ, Zhong L, Zhang L, Ji XP, Zhang M, Zhao YX, Zhang C, Zhang Y. Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br J Pharmacol 2009; 156: 941–51.
75. Rodriguez AE, Granada JF, Rodriguez-Alemparte M, Vigo CF, Delgado J, Fernandez-Pereira C, Pocovi A, Rodriguez-Granillo AM, Schulz D, Raizner AE, Palacios I, O'Neill W, Kaluza GL, Stone G. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis. The Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol 2006; 47: 1522–9.
76. Rodriguez AE, Rodriguez-Granillo AM, Antoniucci D, Mieres J, Fernandez-Pereira C, Rodriguez-Granillo GA, Santaera O, Rubilar B, Palacios IF, Serruys PW. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial. Catheter Cardiovasc Interv 2012; 80: 385–94.
77. Lu J, Ji J, Meng H, Wang D, Jiang B, Liu L, Randell E, Adeli K, Meng QH. The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats. Cardiovasc Diabetol 2013; 12: 58.
78. Rojas LBA, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 2013; 5: 6.
79. Ai D, Jiang H, Westerterp M, Murphy AJ, Wang M, Ganda A, Abramowicz S, Welch C, Almazan F, Zhu Y, Miller YI, Tall AR. Disruption of mammalian target of rapamycin complex 1 in macrophages decreases chemokine gene expression and atherosclerosis. Circ Res 2014; 114: 1576–84.
80. Gouëffic Y, Potter-Perigo S, Chan CK, Johnson PY, Braun K, Evanko SP, Wight TN. Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM. Atherosclerosis 2007; 195: 23–30.
81. Martinet W, Verheye S, De Meyer I, Timmermans J-P, Schrijvers DM, van Brussel I, Bult H, De Meyer GRY. Everolimus triggers cytokine release by macrophages: rationale for stents eluting everolimus and a glucocorticoid. Arterioscler Thromb Vasc Biol 2012; 32: 1228–35.
82. Khurana R, Simons M, Martin JF, Zachary IC. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 2005; 112: 1813–24.
83. Slevin M, Krupinski J, Badimon L. Controlling the angiogenic switch in developing atherosclerotic plaques: possible targets for therapeutic intervention. J Angiogenes Res BioMed Central Ltd 2009; 1: 4.
84. Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol 2009; 218: 8–29.
85. Simon DI, Silverstein RL. Atherothrombosis: seeing red? Circulation 2015; 132: 1860–2.
86. Chistiakov DA, Orekhov AN, Bobryshev YV. Contribution of neovascularization and intraplaque haemorrhage to atherosclerotic plaque progression and instability. Acta Physiol (Oxf) 2015; 213: 539–53.
87. Doyle B, Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol 2007; 49: 2073–80.
88. Chong ZZ, Shang YC, Maiese K. Cardiovascular disease and mTOR signaling. Trends Cardiovasc Med 2011; 21: 151–5.
89. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009; 122: 3589–94.
90. Farhan MA, Carmine-Simmen K, Lewis JD, Moore RB, Murray AG. Endothelial cell mTOR complex-2 regulates sprouting angiogenesis. PLoS One 2015; 10: e0135245.
91. Wang S, Amato KR, Song W, Youngblood V, Lee K, Boothby M, Brantley-Sieders DM, Chen J. Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways. Mol Cell Biol 2015; 35: 1299–313.
92. Vink A, Schoneveld AH, Lamers D, Houben AJS, van der Groep P, van Diest PJ, Pasterkamp G. HIF-1 alpha expression is associated with an atheromatous inflammatory plaque phenotype and upregulated in activated macrophages. Atherosclerosis 2007; 195: e69–75.
93. Miyazawa M, Yasuda M, Fujita M, Kajiwara H, Hirabayashi K, Takekoshi S, Hirasawa T, Murakami M, Ogane N, Kiguchi K, Ishiwata I, Mikami M, Osamura RY. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int 2009; 59: 19–27.
94. Jaipersad AS, Lip GYH, Silverman S, Shantsila E. The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol 2014; 63: 1–11.
95. Lee DF, Hung MC. All roads lead to mTOR: Integrating inflammation and tumor angiogenesis. Cell Cycle 2007; 6: 3011–4.
96. van der Donckt C, van Herck JL, Schrijvers DM, Vanhoutte G, Verhoye M, Blockx I, van der Linden A, Bauters D, Lijnen HR, Sluimer JC, Roth L, van Hove CE, Fransen P, Knaapen MW, Hervent A-S, de Gw K, Bult H, Martinet W, Herman AG, de Meyer GR. Elastin fragmentation in atherosclerotic mice leads to intraplaque neovascularization, plaque rupture, myocardial infarction, stroke, and sudden death. Eur Heart J 2015; 36: 1049–58.
97. Zhai C, Cheng J, Mujahid H, Wang H, Kong J, Yin Y, Li J, Zhang Y, Ji X, Chen W. Selective inhibition of PI3K/Akt/mTOR signaling pathway regulates autophagy of macrophage and vulnerability of atherosclerotic plaque. PLoS One 2014; 9: e90563.
98. Naoum JJ, Woodside KJ, Zhang S, Rychahou PG, Hunter GC. Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice. Transplant Proc 2005; 37: 1880–4.
99. Maiuri MC, Grassia G, Platt AM, Carnuccio R, Ialenti A, Maffia P. Macrophage autophagy in atherosclerosis. Mediators Inflamm 2013; 2013: 584715.
100. Liao X, Sluimer JC, Wang Y, Subramanian M, Brown K, Pattison JS, Robbins J, Martinez J, Tabas I. Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab 2012; 15: 545–53.
101. Ouimet M, Franklin V, Mak E, Liao X, Tabas I, Marcel YL. Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell Metab 2011; 13: 655–67.
102. Wang X, Li L, Niu X, Dang X, Li P, Qu L, Bi X, Gao Y, Hu Y, Li M, Qiao W, Peng Z, Pan L. mTOR enhances foam cell formation by suppressing the autophagy pathway. DNA Cell Biol 2014; 33: 198–204.
103. Holdaas H, Potena L, Saliba F. mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern? Transplant Rev (Orlando) 2015; 29: 93–102.
104. Hofma SH, van Der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, Ligthart JMR, van Essen D, De Feyter PJ, Serruys PW. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 2006; 27: 166–70.
105. Reineke DC, Müller-Schweinitzer E, Winkler B, Kunz D, Konerding MA, Grussenmeyer T, Carrel TP, Eckstein FS, Grapow MTR. Rapamycin impairs endothelial cell function in human internal thoracic arteries. Eur J Med Res 2015; 20: 59.
106. Homs S, Roura G, Gomez-Lara J, Ferreiro JL, Romaguera R, Sanchez-Elvira G, Teruel L, Gomez-Hospital JA, Cequier A. Endothelial vasomotor function after everolimus-eluting stent implantation. Eur Heart J 2013; 34 (Suppl. 1): P3026.
107. Roura G, Homs S, Ferreiro JL, Gomez-Lara J, Romaguera R, Teruel L, Sánchez-Elvira G, Ariza-Solé A, Gómez-Hospital JA, Cequier A. Preserved endothelial vasomotor function after everolimus-eluting stent implantation. EuroIntervention 2015; 11: 643–9.
108. Cheng C, Tempel D, Oostlander A, Helderman F, Gijsen F, Wentzel J, van Haperen R, Haitsma DB, Serruys PW, van der Steen AFW, De Crom R, Krams R. Rapamycin modulates the eNOS vs. shear stress relationship. Cardiovasc Res 2008; 78: 123–9.
109. Wessler JD, Steingart RM, Schwartz GK, Harvey B-G, Schaffer W. Dramatic improvement in pulmonary hypertension with rapamycin. Chest 2010; 138: 991–3.
110. Pascual J, Fernández AM, Marcén R, Ortuño J. Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia – a case report. Nephrol Dial Transplant 2006; 21 (Suppl. 3): iii38–41.
111. Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando) 2014; 28: 126–33.
112. Andreassen AK, Eiskjær H, Gude E, Mølbak D, Stueflotten W, Gullestad L. Development of hypertension in heart transplant recipients treated with everolimus compared to a cyclosporine based regimen. J Heart Lung Transplant 2015; 34: S289.
113. Zhan J-K, Wang Y-J, Wang Y, Wang S, Tan P, Huang W, Liu Y-S. The mammalian target of rapamycin signalling pathway is involved in osteoblastic differentiation of vascular smooth muscle cells. Can J Cardiol 2013; 30: 568–75.
114. Joshi NV, Vesey A, Newby DE, Dweck MR. Will 18 F-sodium fluoride PET-CT imaging be the magic bullet for identifying vulnerable coronary atherosclerotic plaques? Curr Cardiol Rep 2014; 16: 521.
115. Shaalan WE, Cheng H, Gewertz B, McKinsey JF, Schwartz LB, Katz D, Cao D, Desai T, Glagov S, Bassiouny HS. Degree of carotid plaque calcification in relation to symptomatic outcome and plaque inflammation. J Vasc Surg 2004; 40: 262–9.
116. Otsuka F, Sakakura K, Yahagi K, Joner M, Virmani R. Has our understanding of calcification in human coronary atherosclerosis progressed? Arterioscler Thromb Vasc Biol 2014; 34: 724–36.
117. Maurizio Salvadori EB. Long-term outcome of everolimus treatment in transplant patients. Transpl Res Risk Manag 2011; 3: 77–90.
118. Habib A, Karmali V, Polavarapu R, Akahori H, Pachura K, Finn AV. Metformin impairs endothelialization after placement of newer generation drug eluting stents. Atherosclerosis 2013; 229: 385–7.
119. Camici GG, Steffel J, Amanovic I, Breitenstein A, Baldinger J, Keller S, Lüscher TF, Tanner FC. Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. Eur Heart J 2010; 31: 236–42.
120. Tur MD, Garrigue V, Vela C, Dupuy AM, Descomps B, Cristol JP, Mourad G. Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. Transplant Proc 2000; 32: 2783–4.
121. Kasiske BL, de Mattos A, Flechner SM, Gallon L, Meier-Kriesche H-U, Weir MR, Wilkinson A. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 8: 1384–92.
122. Houde VP, Brûlé S, Festuccia WT, Blanchard PG, Bellmann K, Deshaies Y, Marette A. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 2010; 59: 1338–48.
123. Deters M, Kirchner G, Koal T, Resch K, Kaever V. Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats. Dig Dis Sci 2004; 49: 30–7.
124. Ai D, Chen C, Han S, Ganda A, Murphy AJ, Haeusler R, Thorp E, Accili D, Horton JD, Tall AR. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J Clin Invest 2012; 122: 1262–70.
125. Beutner F, Brendel D, Teupser D, Sass K, Baber R, Mueller M, Ceglarek U, Thiery J. Effect of everolimus on pre-existing atherosclerosis in LDL-receptor deficient mice. Atherosclerosis 2012; 222: 337–43.
126. Laplante M, Sabatini DM. An emerging role of mTOR in lipid biosynthesis. Curr Biol 2009; 19: R1046–52.
127. Soliman GA. The integral role of mTOR in lipid metabolism. Cell Cycle 2011; 10: 861–2.
128. Chait A, Bornfeldt KE. Diabetes and atherosclerosis: is there a role for hyperglycemia? J Lipid Res 2009; 50 (Suppl.): S335–9.
129. Goldberg IJ. Why does diabetes increase atherosclerosis? I don't know!. J Clin Invest 2004; 114: 613–5.
130. Kanter JE, Averill MM, Leboeuf RC, Bornfeldt KE. Diabetes-accelerated atherosclerosis and inflammation. Circ Res 2008; 103: e116–7.
131. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108: 1527–32.
132. Blagosklonny MV. TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists. Cell Death Dis 2013; 4: e964.
133. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012; 335: 1638–43.
134. Tzatsos A, Kandror KV. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol. 2006; 26: 63–76.
135. Tremblay F, Brûlé S, Hee Um S, Li Y, Masuda K, Roden M, Sun XJ, Krebs M, Polakiewicz RD, Thomas G, Marette A. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci USA 2007; 104: 14056–61.
136. Ye L, Varamini B, Lamming DW, Sabatini DM, Baur JA. Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2. Front Genet 2012; 3: 177.
137. Das A, Durrant D, Koka S, Salloum FN, Xi L, Kukreja RC. Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative stress and altered contractile protein expression. J Biol Chem 2014; 289: 4145–60.
138. Di Paolo S, Teutonico A, Leogrande D, Capobianco C, Schena PF. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes? J Am Soc Nephrol 2006; 17: 2236–44.
139. Deblon N, Bourgoin L, Veyrat-Durebex C, Peyrou M, Vinciguerra M, Caillon A, Maeder C, Fournier M, Montet X, Rohner-Jeanrenaud F, Foti M. Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br J Pharmacol 2012; 165: 2325–40.
140. Juengel E, Dauselt A, Makarević J, Wiesner C, Tsaur I, Bartsch G, Haferkamp A, Blaheta RA. Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells. Cancer Lett 2012; 324: 83–90.
141. Juengel E, Nowaz S, Makarevi J, Natsheh I, Werner I, Nelson K, Reiter M, Tsaur I, Mani J, Harder S, Bartsch G, Haferkamp A, Blaheta RA. HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A. Mol Cancer 2014; 13: 152.
142. Hassan B, Akcakanat A, Sangai T, Evans KW, Adkins F, Eterovic AK, Zhao H, Chen K, Chen H, Do K-A, Xie SM, Holder AM, Naing A, Mills GB, Meric-Bernstam F. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget 2014; 5: 8544–57.
143. Tsaur I, Makarević J, Hudak L, Juengel E, Kurosch M, Wiesner C, Bartsch G, Harder S, Haferkamp A, Blaheta RA. The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. Cancer Lett 2011; 313: 84–90.
144. Wagle N, Grabiner BC, van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N, Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, Carter SL, Sabatini DM, Jänne PA, Garraway LA, Lorch JH. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med 2014; 371: 1426–33.
145. Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 2013; 123: 2764–72.
146. Zhang J, Yang Z, Xie L, Xu L, Xu D, Liu X. Statins, autophagy and cancer metastasis. Int J Biochem Cell Biol 2013; 45: 745–52.
147. Yang PM, Liu YL, Lin YC, Shun CT, Wu MS, Chen CC. Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res 2010; 70: 7699–709.
148. Hattori Y, Hattori K, Hayashi T. Pleiotropic benefits of metformin: macrophage targeting its anti-inflammatory mechanisms. Diabetes 2015; 64: 1907–9.
149. Sun W, Lee TS, Zhu M, Gu C, Wang Y, Zhu Y, Shyy JYJ. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 2006; 114: 2655–62.
150. Song CW, Lee H, Dings RPM, Williams B, Powers J, Santos TD, Choi B-H, Park HJ. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep 2012; 2: 362.
151. Xu T, Brandmaier S, Messias AC, Herder C, Draisma HHM, Demirkan A, Yu Z, Ried JS, Haller T, Heier M, Campillos M, Fobo G, Stark R, Holzapfel C, Adam J, Chi S, Rotter M, Panni T, Quante AS, He Y, Prehn C, Roemisch-Margl W, Kastenmüller G, Willemsen G, Pool R, Kasa K, van Dijk KW, Hankemeier T, Meisinger C, Thorand B, Ruepp A, Hrabé de Angelis M, Li Y, Wichmann H-E, Stratmann B, Strauch K, Metspalu A, Gieger C, Suhre K, Adamski J, Illig T, Rathmann W, Roden M, Peters A, van Duijn CM, Boomsma DI, Meitinger T, Wang-Sattler R. Effects of metformin on metabolite profiles and LDL cholesterol in patients With type 2 diabetes. Diabetes Care 2015; 38: 1858–67.
152. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'Reilly T, Stolz B, Marti A, Thomas G, Lane HA. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004; 64: 252–61.
153. Baratelli C, Brizzi MP, Tampellini M, Scagliotti GV, Priola A, Terzolo M, Pia A, Berruti A. Intermittent everolimus administration for malignant insulinoma. Endocrinol Diabetes Metab Case Rep 2014; 2014: 140047.
154. Pallet N, Legendre C. Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf 2013; 12: 177–86.
155. Din FVN, Valanciute A, Houde VP, Zibrova D, Green KA, Sakamoto K, Alessi DR, Dunlop MG. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 2012; 142: 1504–15.e3.